$552 billion is wasted annually when patients are prescribed drugs they don’t respond to.
We use a patient’s individual molecular data to ensure optimal therapy is prescribed from day one, improving lives and saving money.
A first-of-its kind blood based molecular signature test identifies a patient’s unique disease biology to determine which drug actually targets the disease, allowing providers and payers to make the right therapy decision to reach treatment goals.
Clinico-genomic data collected from our tested patients and analyzed by our AI platform reveals novel insights into autoimmune diseases, such as novel drug targets specific to biologically similar patient populations.
